Leukeran

Chlorambucil, the active ingredient in Leukeran, is an alkylating agent presented as a tablet for oral use. It is employed in the treatment of chronic lymphocytic leukemia, Hodgkin's lymphoma, non‑Hodgkin's lymphoma and other lymphoid malignancies.\n\nGNH India supplies Leukeran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. Our global network ensures reliable delivery, regulatory compliance and quality assurance for oncology therapeutics.

Leukeran (chlorambucil) is used in the management of lymphoid malignancies, targeting rapidly proliferating cancer cells.\n\nChronic lymphocytic leukemia: induces disease control and can achieve remission.\nHodgkin's lymphoma: contributes to disease remission when used as part of combination therapy.\nNon‑Hodgkin's lymphoma: provides therapeutic benefit and disease stabilization.\nOther lymphoid malignancies: offers clinical benefit as part of treatment regimens.

Chlorambucil may cause a range of adverse reactions, varying from mild to severe.\n\nCommon Side Effects:\n- Nausea: mild to moderate gastrointestinal upset.\n- Fatigue: persistent tiredness.\n- Myelosuppression: decreased blood counts such as neutropenia and anemia.\n- Alopecia: hair thinning or loss.\n\nSerious or Rare Side Effects:\n- Severe neutropenia: increased risk of infection.\n- Secondary malignancies: possible development of other cancers.\n- Pulmonary fibrosis: rare lung scarring.

Before prescribing Leukeran, clinicians should consider several precautionary measures to minimize risks.\n\n- Baseline blood counts: obtain a complete blood count before initiating therapy.\n- Renal and hepatic function: assess kidney and liver status as impairment may affect drug clearance.\n- Pregnancy: contraindicated in pregnancy due to teratogenic risk; avoid use in pregnant women.\n- Concomitant immunosuppressants: monitor for additive bone marrow suppression.\n- Infection risk: advise patients to report signs of infection promptly.\n- Store at ambient temperature: keep tablets below 25°C in original packaging, protect from moisture.

Chlorambucil interacts with several medicines; awareness of these interactions helps prevent adverse outcomes.\n\nMajor Interactions (Avoid):\n- Live vaccines: increased risk of infection; avoid concurrent use.\n- Strong CYP450 inducers (e.g., rifampin): may reduce chlorambucil efficacy.\n- Anticoagulants (e.g., warfarin): heightened bleeding risk due to myelosuppression.\n\nModerate Interactions (Monitor Closely):\n- Other myelosuppressive agents: additive bone marrow toxicity.\n- Allopurinol: may increase chlorambucil plasma levels.\n- NSAIDs: potential for enhanced gastrointestinal irritation.